Active — Not RecruitingPhase 4

OM-85 in Paediatric Recurrent Respiratory Tract Infections With Wheezing Lower Respiratory Illness

Germany525 participantsStarted 2022-12-12

Plain-language summary

This study will assess the efficacy and safety of OM-85 compared to placebo in reducing the number of respiratory tract infections (RTIs) in children aged between 6 months and 5 years.

Who can participate

Age range6 Months – 5 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Injection or oral administration of steroids within 4 weeks prior to study enrolment.
✕. Previous and/or concomitant immunosuppressants, immunostimulants, or gamma globulins within 6 months prior to study enrolment.

What they're measuring

Rate of respiratory tract infections (RTIs)

Timeframe: 12 Months

Trial details

NCT IDNCT05677763

SponsorOM Pharma SA

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-03-10

View on ClinicalTrials.gov More Respiratory Tract Infections trials